News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Columbia Laboratories, Inc. (CBRX) To Discuss Second Quarter 2014 Financial Results On July 31st Conference Call



7/23/2014 12:27:27 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOSTON, July 23, 2014 /PRNewswire/ -- The management team at Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on July 31, 2014, to discuss financial results for the second quarter ended June 30, 2014.  The call details are as follows:

Date:

Thursday, July 31, 2014

Time:

8:30 am EDT

Dial-in numbers:

Toll free: (877) 870-4263 (U.S.), (855) 669-9657 (Canada) or,


International: (412) 317-0790

Webcast (live & archive):

www.columbialabs.com, under 'Investor' or click here

The teleconference replay will be available approximately one hour after completion through Thursday, August 7, 2014, at (877) 344-7529 (U.S.), (855) 669-9658 (Canada) or (412) 317-0088 (International). The conference ID for the replay is 10049906.  The archived webcast will be available for one year via the aforementioned URLs.

About Columbia Laboratories

Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry.  The Company has a successful heritage in developing pharmaceutical products, particularly in women's health.  Its most successful product to date, CRINONE® 8% (progesterone gel), is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide.  For more information, please visit www.columbialabs.com.

CRINONE® is a registered trademark of Actavis, Inc. in the U.S.

Contact:
MBS Value Partners
Katja Buhrer
+212 661 7004
katja.buhrer@mbsvalue.com

SOURCE Columbia Laboratories, Inc.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES